Dual Targeting Ligands-Histamine H₃ Receptor Ligands with Monoamine Oxidase B Inhibitory Activity-In Vitro and In Vivo Evaluation

• Príomhchruthaitheoirí: Dorota Łażewska (Údar), Agata Siwek (Údar), Agnieszka Olejarz-Maciej (Údar), Agata Doroz-Płonka (Údar), Anna Wiktorowska-Owczarek (Údar), Marta Jóźwiak-Bębenista (Údar), David Reiner-Link (Údar), Annika Frank (Údar), Wioletta Sromek-Trzaskowska (Údar), Ewelina Honkisz-Orzechowska (Údar), Ewelina Królicka (Údar), Holger Stark (Údar), Marek Wieczorek (Údar), Waldemar Wagner (Údar), Katarzyna Kieć-Kononowicz (Údar), Anna Stasiak (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: MDPI AG, 2022-10-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

The clinical symptoms of Parkinson's disease (PD) appear when dopamine (DA) concentrations in the striatum drops to around 20%. Simultaneous inhibitory effects on histamine H₃ receptor (H₃R) and MAO B can increase DA levels in the brain. A series of...